Name: "Anti-IGFBP-2 h(CD28-CD3_) CAART, pCDCAAR1"
Availability: InStock

"Anti-IGFBP-2 h(CD28-CD3_) CAART, pCDCAAR1" | Creative Biolabs

CAAR-Ts represent a targeted approach to therapy of antibody-mediated autoimmune diseases, with the potential for generation of long-term memory CAAR-Ts that can potentially cure disease. Autoantigen-based chimeric immunoreceptors (CAAR) can direct T cells to kill autoreactive B lymphocytes through the specificity of the B cell receptor (BCR). The vector of anti-IGFBP-2 chimeric autoantigen receptor (CAAR) is constructed for the engineering of T cells to target Human IGFBP-2. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-IGFBP-2 antibody linked to lung-cancer.